Vyndamax
| Chemical Name | tafamidis |
| Dosage Form | Capsule (oral; 61 mg) |
| Drug Class | Inhibitors |
| System | Cardiovascular |
| Company | Pfizer |
| Approval Year | 2019 |
Indication
- For the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization